Colorectal cancer, also known as bowel cancer and colon cancer, is the development of the cancer in the colon or rectum. A cancer is the abnormal growth of the cells that have the ability to invade or spread to the other parts of the body. Colorectal cancer begins when the healthy cells in the lining of the colon or rectum changes and grows out of control, forming a mass called tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread. These changes usually take years to develop.

Screening for colorectal cancer is effective not only for early detection but also for prevention. Diagnosis of colorectal cancer through screening tends to occur 2-3 years before diagnosis of cases with symptoms. CRC Screening is broadly divided into Structural Examination and Stool Tests. Structural examination is further divide into Flexible Sigmoidography, Colonoscopy and Computed Tomographic Colonography, whereas Stool Tests are divided into Occult blood and DNA tests.

Colorectal cancer diagnostic market is expected to grow in future due to increasing disposable income, increasing ageing population and cancer incidences and rising healthcare expenditure. Key trends of this market include launch of branded and advanced diagnosis and technology innovation. However, there are some factors which can hinder the market growth including stringent legal norms, high cost, need for high quality of screening process and dearth of expertise.

The report “Colorectal Cancer Diagnostics Market with Focus on DNA-based Tests: Industry Analysis & Outlook (2018-2025)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and Asia. The report profiles the key players of the market including Epigenomics, Exact Sciences Corporation, VoilitionRx Ltd and Quest Diagnostics.